Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) refractory to H1 antihistamines at the time of randomization.~Exclusion Criteria:~* Treatment with an investigational agent within 30 days prior to screening.~* Weight \< 20 kg (44 lbs).~* Clearly defined underlying etiology for chronic urticarias other than CIU.~* Evidence of parasitic infection.~* Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or other skin disease associated with itch.~* Previous treatment with omalizumab within a year prior to screening.~* Routine doses of the following medications within 30 days prior to screening: Systemic or cutaneous (topical) corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide.~* Intravenous (IV) immunoglobulin G (IVIG), or plasmapheresis within 30 days prior to screening.~* Regular (daily/every other day) doxepin (oral) use within 6 weeks prior to screening.~* Any H2 antihistamine use within 7 days prior to screening.~* Any leukotriene receptor antagonist (LTRA) (montelukast or zafirlukast) within 7 days prior to screening.~* Any H1 antihistamines at greater than approved doses within 3 days prior to screening.~* Patients with current malignancy, history of malignancy, or currently under work-up for suspected malignancy except non-melanoma skin cancer that has been treated or excised and is considered resolved.~* Hypersensitivity to omalizumab or any component of the formulation.~* History of anaphylactic shock.~* Presence of clinically significant cardiovascular, neurological, psychiatric, metabolic, or other pathological conditions that could interfere with the interpretation of the study results and or compromise the safety of the patients.~* Evidence of current drug or alcohol abuse.~* Nursing women or women of childbearing potential, unless they meet the following definition of post-menopausal: 12 months of natural amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \> 40 mIU/mL or 6 weeks post surgical bilateral oophorectomy (with or without hysterectomy) or hysterectomy or are using one or more of the following acceptable methods of contraception: surgical sterilization, hormonal contraception, and double-barrier methods.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
- Omalizumab 75 mg (Type: EXPERIMENTAL): Participants received omalizumab 75 mg subcutaneously every 4 weeks during the 24 week treatment period.
- Omalizumab 150 mg (Type: EXPERIMENTAL): Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24 week treatment period.
- Omalizumab 300 mg (Type: EXPERIMENTAL): Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).